Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Valerius

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Frontiers in Immunology|September 19, 2022
Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibodyCarina Lynn Gehlert, Pegah Rahmati, Ammelie Svea Boje, et al.
Molecular Cancer Therapeutics|July 3, 2024
Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0Chilam Chan, J H Marco Jansen, Ilona S T Hendriks, et al.
Frontiers in Immunology|June 22, 2023
Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cellsMarta Lustig, Chilam Chan, J H Marco Jansen, et al.
Cancer|June 3, 2023
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party studyRama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
British Journal of Haematology|February 23, 2018
New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodiesSaskia Meyer, Mitchell Evers, Johannes H M Jansen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 4, 2016
Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B CellsPatrick J Engelberts, Marleen Voorhorst, Janine Schuurman, et al.
Blood|June 3, 2004
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasJessica L Teeling, Ruth R French, Mark S Cragg, et al.
Blood|June 21, 2008
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cellsMatthias Peipp, Jeroen J Lammerts van Bueren, Tanja Schneider-Merck, et al.
PNAS Nexus|March 5, 2025
Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-lifeSimone Mester, Chilam Chan, Marta Lustig, et al.
Journal of Immunological Methods|August 23, 2011
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCCRoland Repp, Christian Kellner, Anja Muskulus, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Frontiers in Immunology|September 19, 2022
Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibodyCarina Lynn Gehlert, Pegah Rahmati, Ammelie Svea Boje, et al.
Molecular Cancer Therapeutics|July 3, 2024
Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0Chilam Chan, J H Marco Jansen, Ilona S T Hendriks, et al.
Frontiers in Immunology|June 22, 2023
Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cellsMarta Lustig, Chilam Chan, J H Marco Jansen, et al.
Cancer|June 3, 2023
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party studyRama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
British Journal of Haematology|February 23, 2018
New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodiesSaskia Meyer, Mitchell Evers, Johannes H M Jansen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 4, 2016
Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B CellsPatrick J Engelberts, Marleen Voorhorst, Janine Schuurman, et al.
Blood|June 3, 2004
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasJessica L Teeling, Ruth R French, Mark S Cragg, et al.
Blood|June 21, 2008
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cellsMatthias Peipp, Jeroen J Lammerts van Bueren, Tanja Schneider-Merck, et al.
PNAS Nexus|March 5, 2025
Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-lifeSimone Mester, Chilam Chan, Marta Lustig, et al.
Journal of Immunological Methods|August 23, 2011
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCCRoland Repp, Christian Kellner, Anja Muskulus, et al.
Pageof 11